Academic Highlights summarize faculty presentations from symposia, roundtable meetings, and teleconferences. They include case-based questions that help learners pause for reflection on key clinical messages. Many are CME accredited.
Even brief interruptions in treatment can significantly increase a schizophrenia patient's risk of psychotic relapse. Read this Academic Highlights to discover the complex factors that can contribute to treatment interruptions in patients with schizophrenia, learn the most effective methods for monitoring adherence, and gain useful strategies for ensuring continuous treatment.
Pregnancy labeling of prescription medications in the US is in the midst of a major transformation. Are you aware of the changes? Read this summary of a recent conference including representatives from academia, industry, and the goverment to bring yourself up to date on the new labeling system.
Insomnia is often considered a symptom of psychiatric disorders when it actually needs to be addressed as a separate disorder. Read this CME Academic Highlights in which experts discuss ways to evalute patients with insomnia and to safely and effectively implement behavioral and pharmacologic treatments.
Many of your patients with depression also experience anxiety symptoms, and addressing these symptoms is a crucial part of successful treatment. Explore this free Academic Highlights activity to learn about the newly added anxious distress specifier in the DSM-5, ways to recognize anxiety symptoms in MDD patients, and treatment strategies you can use in your practice.
Is cognitive impairment keeping your patients with MDD from achieving full functional recovery? In this Academic Highlights, leading experts in MDD discuss the burden associated with cognitive impairment, effective strategies for assessing cognitive function, and available pharmacologic and nonpharmacologic treatment options.
Descriptions of mixed states can be found in the writings of ancient Greek physicians, and the concept continues to be refined. In this CME activity, join experts as they review the current diagnostic criteria for depressive episodes with mixed features, the risk of developing bipolar disorder in patients with this diagnosis, and recent treatment guidelines.
Is your patient experiencing involuntary movements of the face, torso, or extremities? It could be tardive dyskinesia, a side effect of antipsychotic medications. Explore this CME Academic Highlights activity to find out who's at risk for developing tardive dyskinesia and how it can be prevented. Plus, learn about assessment strategies and tools as well as evidence for treatments.
What can you do for your patients with depression who show partial response or no response to treatment? Follow a discussion by expert faculty about how altering levels of dopamine, norepinephrine, and serotonin in the brain may theoretically target specific depressive symptoms and how the mechanisms of action of different antidepressant classes are associated with therapeutic benefits and adverse effects.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”